SCHEMBL24454

SCHEMBL24454

Fc1ccc(-c2c(CBr)c(C3CC3)nc3ccccc23)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKAA2 P54646 1/20 0.77
RXRA P19793 2/20 0.54
NR1I2 O75469 1/20 0.50
NR4A2 P43354 1/20 0.50
PDE4D Q08499 1/20 0.50
HMGCR P04035 2/20 0.48
ADORA2A P29274 1/20 0.40
HPGD P15428 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
TNKS O95271 1/20 0.38
TNKS2 Q9H2K2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29419455 1.00 PRKAA2 (0.77) PRKAA2RXRANR1I2NR4A2PDE4D
SCHEMBL27932414 0.90 PRKAA2 (0.73) PRKAA2RXRANR1I2NR4A2PDE4D
SCHEMBL29419156 0.87 PRKAA2 (0.77) PRKAA2RXRANR1I2NR4A2PDE4D
SCHEMBL30060873 0.87 PRKAA2 (1.00) PRKAA2RXRANR1I2NR4A2PDE4D
SCHEMBL14753495 0.87 PRKAA2 (0.77) PRKAA2RXRANR1I2NR4A2PDE4D
SCHEMBL14749820 0.87 PRKAA2 (0.77) PRKAA2RXRANR1I2NR4A2PDE4D
SCHEMBL31546 0.87 PRKAA2 (1.00) PRKAA2RXRANR1I2NR4A2PDE4D
SCHEMBL3709827 0.87 PRKAA2 (0.77) PRKAA2RXRANR1I2NR4A2PDE4D
SCHEMBL28803542 0.84 PRKAA2 (0.68) PRKAA2RXRANR1I2NR4A2PDE4D
SCHEMBL9115745 0.84 PRKAA2 (0.72) PRKAA2RXRANR1I2NR4A2PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113651802-B One-pot preparation method of pitavastatin calcium intermediate 天地恒一制药股份有限公司 2022-03-29 CN claimed
CN-113651802-A One-pot preparation method of pitavastatin calcium intermediate 天地恒一制药股份有限公司 2021-11-16 CN claimed
CN-110407818-A A kind of preparation method of Pitavastatin Calcium intermediate ANQING ENJU BIO MEDICINE TECH CO LTD 2019-11-05 CN claimed
US-11814355-B2 Method for synthesizing pitavastatin t-butyl ester ANHUI QINGYUN PHARMACEUTICAL AND CHEMICAL CO., LTD. (CN) 2023-11-14 US disclosed
CN-116947922-A Synthesis process of pitavastatin intermediate 江苏福瑞康泰药业有限公司 2023-10-27 CN disclosed
CN-113651802-B One-pot preparation method of pitavastatin calcium intermediate 天地恒一制药股份有限公司 2022-03-29 CN disclosed
CN-113651802-B One-pot preparation method of pitavastatin calcium intermediate 天地恒一制药股份有限公司 2022-03-29 CN disclosed
CN-113651802-A One-pot preparation method of pitavastatin calcium intermediate 天地恒一制药股份有限公司 2021-11-16 CN disclosed
CN-113651802-A One-pot preparation method of pitavastatin calcium intermediate 天地恒一制药股份有限公司 2021-11-16 CN disclosed
CN-108822090-B Preparation method of statin drug intermediate 杭州乐敦科技有限公司 2020-11-17 CN disclosed
CN-110407818-A A kind of preparation method of Pitavastatin Calcium intermediate ANQING ENJU BIO MEDICINE TECH CO LTD 2019-11-05 CN disclosed
US-20090275752-A1 Novel Process for Statins and its Pharmaceutically Acceptable Salts Thereof MSN LABORATORIES LIMITED (IN) 2009-11-05 US disclosed
US-20090275752-A1 Novel Process for Statins and its Pharmaceutically Acceptable Salts Thereof MSN LABORATORIES LIMITED (IN) 2009-11-05 US disclosed
US-20090275752-A1 Novel Process for Statins and its Pharmaceutically Acceptable Salts Thereof MSN LABORATORIES LIMITED (IN) 2009-11-05 US disclosed
EP-1631533-B1 NOVEL PROCESS FOR STEREOSELECTIVE REDUCTION OF BETA-KETOESTERS BIOCON LTD (IN) 2009-03-11 EP disclosed
EP-2024341-A2 NOVEL PROCESS FOR STATINS AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF Satynarayana Reddy, Manne (IN) 2009-02-18 EP disclosed
WO-2007132482-A2 NOVEL PROCESS FOR THE PREPARATION OF PITAVASTATIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS SATYANARAYANA REDDY MANNE (IN) 2007-11-22 WO disclosed
WO-2007132482-A2 NOVEL PROCESS FOR THE PREPARATION OF PITAVASTATIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS SATYANARAYANA REDDY MANNE (IN) 2007-11-22 WO disclosed
WO-2007125547-A2 NOVEL PROCESS FOR STATINS AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF SATYANARAYANA REDDY MANNE (IN) 2007-11-08 WO disclosed
WO-1995011898-A1 CONDENSED PYRIDINE TYPE MEVALONOLACTONE INTERMEDIATE AND PROCESS FOR ITS PRODUCTION NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1995-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814355-B2 Method for synthesizing pitavastatin t-butyl ester SSTR4, DPP4, VIP PRKAA2 234/4885RXRA 1209/4885NR1I2 4055/4885
US-20090275752-A1 Novel Process for Statins and its Pharmaceutically Acceptable Salts Thereof HMGCR, NPC1L1, PCSK9 PRKAA2 1726/4885RXRA 1958/4885NR1I2 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.